August 21, 2020
Exo, a Silicon Valley company known for its in-development handheld ultrasound device, announced $40 million in new funding yesterday. GlaxoSmithKline's Investor Action Potential Venture Capital fund was among the Series B+ round's unnamed investors.
Exo said in its announcement that it will be using the funds to wrap up product development for that device, and to bring its data and workflow apps...
May 17, 2018
Sanofi’s approach to digital health is broad, but focused, Rachel Sha, the company’s vice president of digital business development and licensing, told MobiHealthNews in an interview ahead of the upcoming BIO 2018 conference in Boston, where Sha will be speaking on a range of digital health-related topics.
“At Sanofi we’re lucky in the sense that we have a very clear set of digital priorities...
May 3, 2018
Garmin and the University of Kansas Medical Center are taking a closer look at the role wearables can play in detecting and managing medical conditions, the groups announced earlier this week. Initially focused on sleep apnea and atrial fibrillation, the collaboration is a clear step beyond the fitness and wellness realm to which Garmin’s wearables have so far been limited.
“Garmin Health is...
April 24, 2018
Today, remote clinical trial company Science 37 and diagnostic clinical decision support system maker VisualDx have announced an effort to jointly engage patients and clinicians in their respective networks. The partnership will give VisualDx users access to Science 37’s clinical trial research platform, while those within Science 37’s network will be able to view VisualDx’s skin health medical...
March 9, 2018
Predictive analytics platform Clew Medical has recently announced its partnership with WakeMed for its clinical trials in the eICU to detect patient deterioration in realtime. Clew uses machine learning algorithms and customized physiological models to help clinicians make decisions with actionable clinical, operational and financial insights. The company’s AI system will give WakeMed access to...
December 8, 2017
Otsuka Pharmaceuticals has deepened its relationship with Science 37, a startup it invested in earlier this year. Otsuka will use Science 37’s mobile clinical trial technology to further digitize its own trials, with an initial focus on psychiatry and behavioral health.
“Otsuka is dedicated to promoting innovation in clinical trials as a means of expanding the diversity of patients enrolled in...
December 1, 2017
With billions of dollars and countless hours of human effort spent each year validating new drugs, devices, and medical interventions, it’s little surprise that the healthcare industry is turning to technology to streamline the process. From participant recruitment to data collection to adherence, clinical trials are rife with logistical challenges similar to those already being addressed by...
October 24, 2017
Los Angeles-based research company Science 37 announced the completion of a clinical study for AOBiome Therapeutics conducted entirely through a smartphone app.
The Phase 2b study ran on the back of Science 37’s mobile Network Oriented Research Assistant (NORA) platform, which allows for real-time video chat, customized self-photography models, data collection, and electronic consent. Science 37...
July 6, 2017
San Francisco-based Mendel.ai, a startup that is developing an artificial intelligence-powered platform to match people with cancer to clinical trials, has raised $2 million in seed funding from DCM Ventures, BootstrapLabs, Indie Bio, LaunchCapital and SOSV. Medel.ai will use the capital to forge partnerships with hospitals and cancer genomics companies to bring the system into use.
April 25, 2017
Remote clinical trial company Science 37 has raised $29 million in a round led by Glynn Capital Management with participation from Google's investment arm GV. One more new investor -- AmGen ventures -- contributed, as did existing investors Lux Capital, Redmile Group, dRx Capital, and Sanofi Ventures. It's a large round with impressive investors, but it is technically a down round from last fall'...